Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A pharmaceutical composition for the treatment of IL-6 related diseases, comprising an interleukin 6 antagonist (IL-6 antagonist) and an immunosuppressant.

2. (Original) A pharmaceutical composition comprising immunosuppressants, for effect enhancement on the use of IL-6 antagonist for the treatment of IL-6 related diseases.

3. (Original) A pharmaceutical composition comprising immunosuppressants, for the reduction or prevention of allergic reactions upon the treatment of IL-6 related diseases with an IL-6 antagonist.

4. (Original) A therapeutic agent for the administration at high doses, comprising an IL-6 antagonist.

5. (Original) A pharmaceutical composition comprising a high dose of IL-6 antagonist, for the reduction or prevention of allergic reactions upon the treatment of IL-6 related diseases.

6. (Previously Presented) The pharmaceutical composition according to claim 1, wherein said IL-6 antagonist is an anti-interleukin-6 receptor antibody (IL-6R antibody).

7. (Original) The pharmaceutical composition according to claim 6, wherein said IL-6R antibody is a monoclonal antibody against IL-6R.

8. (Previously Presented) The pharmaceutical composition according to claim 6, wherein said anti-IL-6R antibody is a monoclonal antibody against human IL-6R.

9. (Previously Presented) The pharmaceutical composition according to claim 6, wherein said anti-IL-6R antibody is a monoclonal antibody against mouse IL-6R.

10. (Previously Presented) The pharmaceutical composition according to claim 6, wherein said anti-IL-6R antibody is a recombinant antibody.

11. (Original) The pharmaceutical composition according to claim 8, wherein said human anti-IL-6R monoclonal antibody is PM-1 antibody.

12. (Original) The pharmaceutical composition according to claim 9, wherein said mouse IL-6R monoclonal antibody is MR16-1 antibody.

13. (Previously Presented) The pharmaceutical composition according to claim 6, wherein said anti-IL-6R antibody is a chimera antibody, a humanized antibody or a human type antibody against IL-6R.

14. (Original) The pharmaceutical composition according to claim 13, wherein said humanized antibody against IL-6R is humanized PM-1 antibody.

15. (Previously Presented) The pharmaceutical composition according to claim 1, wherein said IL-6 related diseases are rheumatoid arthritis, plasmacytosis, hyperimmunoglobulinemia, anemia, nephritis, cachexia, multiple myeloma, Castleman's disease, mesangial proliferative nephritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, pancreatitis, psoriasis, juvenile idiopathic arthritis or systematic juvenile idiopathic arthritis, vasculitis and Kawasaki disease.

16. (Previously Presented) The pharmaceutical composition according to claim 6, which is said pharmaceutical composition comprising the immunosuppressant or said pharmaceutical composition comprising the antibody and the immunosuppressant, wherein a dosage of anti-IL-6R antibody is from 0.02 to 150 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.

17. (Original) The pharmaceutical composition according to claim 16, wherein the dosage of anti-IL-6R antibody is from 0.5 to 30 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.

18. (Original) The pharmaceutical composition according to claim 17, wherein the dosage of anti-IL-6R antibody is from 2 to 8 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.

19. (Previously Presented) The pharmaceutical composition according to claim 4, which is said therapeutic agent for the treatment of IL-6 related diseases for the administration at high doses, comprising the anti-IL-6R antibody or said pharmaceutical composition comprising high doses of the anti-IL-6R antibody, wherein the dosage of anti-IL-6R antibody is 4 mg/kg/4 weeks or more or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.

20. (Original) The pharmaceutical composition according to claim 19, wherein the dosage of anti-IL-6R antibody is from 6 to 16 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.

21. (Original) The pharmaceutical composition according to claim 20, wherein the dosage of anti-IL-6R antibody is from 6 to 10 mg/kg/4 weeks or the dosage showing an anti-IL-6R antibody concentration in blood equivalent thereto.

22. (Previously Presented) The pharmaceutical composition according to claim 1, wherein said immunosuppressant is methotrexate (MTX).

23. (Original) The pharmaceutical composition according to claim 22, wherein the dosage of said MTX is from 1 to 100 mg/body/week.

24. (Original) The pharmaceutical composition according to claim 23, wherein the dosage of said MTX is from 4 to 50 mg/body/week.

25. (Original) The pharmaceutical composition according to claim 24, wherein the dosage of said MTX is from 7.5 to 25 mg/body/week.

26. (Previously Presented) The pharmaceutical composition according to claim 1, for simultaneously administering said anti-IL-6 antibody and said immunosuppressant.

27. (Previously Presented) The pharmaceutical composition according to claim 1, for administering said anti-IL-6 antibody and said immunosuppressant with time interval.

28. – 54. (Cancelled)

55. (Previously Presented) A method for treating an IL-6 related disease, comprising administering an IL-6 antagonist and an immunosuppressant to a patient requiring such a treatment.

56. (Original) A method for the effect enhancement on the use of an IL-6 antagonist for the treatment of IL-6 related diseases, comprising administering immunosuppressants and an IL-6 antagonist to a patient requiring such a treatment.

57. (Previously Presented) A method for reducing or preventing an allergic reaction upon treatment of IL-6 related diseases with an IL-6 antagonist, comprising administering an immunosuppressant and an IL-6 antagonist to a patient requiring such a treatment.

58. (Previously Presented) A method for treating an IL-6 related disease, comprising administering an anti-IL-6R antibody at a high dose to a patient requiring such a treatment.

59. (Previously Presented) A method for reducing or preventing an allergic reaction upon treatment of an IL-6 related disease, comprising administering a high dose administration of an IL-6 antagonist to a patient requiring such a treatment.

60. (Previously Presented) The method according to claim 55, wherein said IL-6 antagonist is an anti-IL-6R antibody.

61. (Previously Presented) The method according to claim 55, wherein said anti-IL-6R antibody is a monoclonal antibody against human IL-6R.

62. (Previously Presented) The method according to claim 58, wherein said anti-IL-6R antibody is a monoclonal antibody against mouse IL-6R.

63. (Previously Presented) The method according to claim 60, wherein said anti-IL-6R antibody is a recombinant antibody.

64. (Original) The method according to claim 61, wherein said human anti-IL-6R monoclonal antibody is PM-1 antibody.

65. (Previously Presented) The method according to claim 61, wherein said mouse anti-IL-6R monoclonal antibody is MR16-1 antibody.

66. (Previously Presented) The method according to claim 60, wherein said anti-IL-6R antibody is a chimera antibody, a humanized antibody or a human type antibody against IL-6R.

67. (Original) The method according to claim 66, wherein said humanized antibody against IL-6R is humanized PM-1 antibody.

68. (Previously Presented) The method according to claim 55, wherein said IL-6 related diseases are rheumatoid arthritis, plasmacytosis, hyperimmunoglobulinemia, anemia, nephritis, cachexia, multiple myeloma, Castleman's disease, mesangial proliferative nephritis, systemic lupus erythematosus, Crohn's disease, pancreatitis, psoriasis, juvenile idiopathic arthritis, or systematic juvenile idiopathic arthritis.

69. (Previously Presented) The method according to claim 60, wherein an anti-IL-6R antibody is administered in a dosage from 0.02 to 150 mg/kg/4 weeks.

70. (Previously Presented) The method according to claim 69, wherein the dosage of anti-IL-6R antibody is from 0.5 to 30 mg/kg/4 weeks.

71. (Previously Presented) The method according to claim 70, wherein the dosage of anti-IL-6R antibody is from 2 to 8 mg/kg/4 weeks.

72. (Previously Presented) The method according to claim 58, wherein the dosage of anti-IL-6R antibody is 4 mg/kg/4 weeks or more.

73. (Previously Presented) The method according to claim 72, wherein the dosage of anti-IL-6R antibody is from 6 to 16 mg/kg/4 weeks.

74. (Previously Presented) The method according to claim 73, wherein the dosage of anti-IL-6R antibody is from 6 to 10 mg/kg/4 weeks.

75. (Previously Presented) The method according to claim 55, wherein said immunosuppressant is methotrexate (MTX).

76. (Previously Presented) The method according to claim 75, wherein the MTX is administered in a dosage from 1 to 100 mg/body/week.

77. (Original) The method according to claim 76, wherein the dosage of said MTX is from 4 to 50 mg/body/week.

78. (Original) The method according to claim 77, wherein the dosage of said MTX is from 7.5 to 25 mg/body/week.

79. (Previously Presented) The method according to claim 60, wherein the anti-IL-6R antibody and said immunosuppressant are administered simultaneously.

80. (Previously Presented) The method of claim 60, wherein the anti-IL-6R antibody and said immunosuppressant are administered with in a time interval.